Mereo Biopharma Group PLC 10-Q quarterly reports

Mereo BioPharma Group plc filed its Q2 2026 10-Q, detailing continued net losses, reduced R&D spending, and a significant new licensing agreement for alvelestat.

Mereo BioPharma reports a narrower net loss for Q1 2026 compared to the prior year, driven by lower administrative expenses and foreign currency gains, alongside increased R&D spending primarily on setrusumab.

Mereo BioPharma Group PLC reported a reduced net loss for Q3 2025, driven by non-operating gains, but saw a significant decrease in cash and reiterated the need for future funding.

Mereo BioPharma reported an increased net loss in Q2 2025, driven by higher R&D for setrusumab, while securing a new milestone payment and extending its cash runway into 2027.

Mereo BioPharma Group reports a net loss of $12.9 million for Q1 2025, while advancing its rare disease therapeutic pipeline.

Mereo BioPharma's Q3 2024 report shows a net loss of $15 million, but the company's cash position is strong following a recent capital raise.

Mereo BioPharma reports its financial results for the second quarter of 2024, highlighting a recent capital raise and clinical progress with its lead drug candidate.

Mereo BioPharma Group's Q1 2024 report shows a reduced net loss compared to the same period last year, alongside updates on clinical trials and financial position.